Chemiluminometric determination of tissue polypeptide antigen (TPA), cancer antigen 15-3 (CA 15-3), carcinoembryonic antigen (CEA) in comparison with vascular endothelial growth factor (VEGF) in follow-up of breast cancel

Luminescence

Volumn 15, Issue 5, 2000, Pages 283-289

  Findeisen, Rainer ^a   Albrecht, Steffen ^b   Richter, Barbara ^b   Deutschmann, Kersten ^b   Zimmermann, Thomas ^b   Distler, Wolfgang ^b  

^a ACADEMIC TEACHING HOSPITAL DRESDEN FRIEDRICHSTADT   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Breast cancer; Cancer antigen 15 3 (CA 15 3); Carcinoembryonic antigen (CEA); Chemiluminescence immunoassay; Tissue polypeptide antigen (TPA); Vascular endothelial growth factor (VEGF)

Indexed keywords

CHEMILUMINESCENCE; DIAGNOSIS; DISEASES; ENDOTHELIAL CELLS; IMMUNOLOGY; PATIENT TREATMENT; TUMORS;

BREAST CANCER; CANCER ANTIGEN 15-3; CANCER PATIENTS; CARCINOEMBRYONIC ANTIGEN; CHEMILUMINESCENCE IMMUNOASSAY; CONTROL GROUPS; TISSUE POLYPEPTIDE ANTIGEN; VASCULAR ENDOTHELIAL GROWTH FACTOR;

ANTIGENS;

CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; ENDOTHELIAL CELL GROWTH FACTOR; LYMPHOKINE; TISSUE PLASMINOGEN ACTIVATOR; TUMOR MARKER; VASCULOTROPIN; VASCULOTROPIN A;

ADULT; AGED; ARTICLE; BLOOD; BREAST TUMOR; CANCER STAGING; CHEMOLUMINESCENCE; COMPARATIVE STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; METHODOLOGY; MIDDLE AGED; PATHOLOGY; ROC CURVE; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CA-15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CHEMILUMINESCENT MEASUREMENTS; ENDOTHELIAL GROWTH FACTORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOKINES; MIDDLE AGED; NEOPLASM STAGING; ROC CURVE; SENSITIVITY AND SPECIFICITY; TISSUE PLASMINOGEN ACTIVATOR; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0034268165     PISSN: 15227235     EISSN: None     Source Type: Journal    
DOI: 10.1002/1522-7243(200009/10)15:5<283::aid-bio593>3.0.co;2-f     Document Type: Article

References (30)

1. Becker N, Wahrenburg J. Krebsatlas der Bundesrepublik Deutschland 1981-1990, 3rd edn. Springer: Berlin, 1997; 366 pp.
2. National Cancer Institute of the USA. Cancer Mortality in the US. 1950-1977. National Cancer Institute: 1970; 164-173.
3. Martius G, Knapstein PG (eds). Das Mammakarzinom. Interdisziplinäre Diagnostik, Therapie und Nachsorge. Stuttgart: Ferdinand Enke Verlag, 1994.
4. Hayes DF (ed.). Brustkrebs. Berlin, Wiesbaden: Ullstein Mosby GmbH, 1995.
5. Siebert W. editor. Aktuelle adjuvante Therapie des Mammakarzinoms. München: Hans Marseille Verlag GmbH, 1997.
6. Findeisen R, Albrecht S, Zimmermann T, Richter B, Deutschmann K, Distler W. Chemiluminometric immunoassay of tissue polypeptide antigen (TPA) in cases of breast cancer. J. Biolumin. Chemilumin. 1998; 13: 246 (abstr).
7. Ferrara N, Henzel WJ. Pituitarity follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Commun. 1989; 161: 851-858.
8. Senger RD, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219: 983-985.
9. Plouet J, Schilling J, Gospodarowicz D. Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT-20 cells. EMBO J. 1989; 8: 3801-3806.
10. Ibelgauft H. Lexikon Zytokine. München: Medicon Verlag, 1992; 267-268.
11. Ferrara N, Winer J, Burton T. Aortic smooth muscle cell express and secrete vascular endothelial growth factor. Growth Factors 1991; 5: 141-148.
12. Brown LF, Yeo KT, Berse B, Yeo TK, Senger DR, Dvorak HF, van de Water L. Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. J. Exp. Med. 1992; 176: 1375-1379.
13. Brown LF, Berse B, Tognazzi K, Manseau EJ, Van de Water L, Senger DR, Dvorak HF, Rosen S. Vascular permeability factor mRNA and protein expression in human kidney. Kidney Int. 1992; 42: 1457-1461.
14. Iijima K, Yoshikawa N, Connolly DT, Nakamura H. Human mesangial cells and peripheral blood mononuclear cells produce vascular permeability factor. Kidney Int. 1993; 44: 959-966.
15. Fava RA, Olsen NJ, Spencer Green G, Yeo KT, Yeo TK, Berse B, Jackman RW, Senger DR, Dvorak HF, Brown LF. Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J. Exp. Med. 1994; 180: 341-346.
16. Connolly DT. Vascular permeability factor: a unique regulator of blood vessel function. J. Cell Biochem. 1991; 47: 219-223.
17. Schott RJ, Morrow LA. Growth factors and angiogenesis. Cardiovasc. Res. 1993; 27: 1155-1161.
18. Ferrara N, Houck K, Jakeman L, Leung DW. Molecular and biolocical properties of the vascular endothelial growth factor family of proteins. Endocr. Rev. 1992; 13: 18-32.
19. Neufeld G, Tessler S, Gitay-Goren H, Cohen T, Levi BZ. Vascular endothelial growth factor and its receptors. Prog. Growth Factor Res. 1994; 5: 89-97.
20. Senger RD, van de Water L, Brown LF, Nagy JA, Yeo KT, Yeo TK, Berse B, Jackman RW, Dvorak AM, Dvorak HF. Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev. 1993; 12: 303.
21. Hermanek L, Sorbin H (eds). TNM Klassifikation maligner Tumoren, 4th edn. Berlin: Akademie-Verlag, 1989; 99 pp.
22. Toi M, Inada K, Suzuki H, Tominaga T. Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor. Breast Cancer Res. Treatm. 1995; 36: 193-205.
23. Wright PS, Loudy DE, Cross-Doersen DE, Montgomery LR, Sprinkle-Cavallo J, Miller JA, Distler CM, Lower EE, Woessner RD. Quantitation of vascular endothelial growth factor mRNA levels in human breast tumors and metastatic lymph nodes. Exp. Mol. Pathol. 1997; 64: 41-51.
24. Donovan D, Harmey JH, Toomey D, Osborne H, Redmond HP, Bouchier-Hayes DJ. TGFβ-1 regulation of VEGF production by breast cancer cells. Ann. Surg. Oncol. 1997; 4: 621-627.
25. Toi M, Hoshina S, Takayanagi T, Tominaga T. Association of vascular endothelial growth factor expression with tumor angiogenesis and with earls relapse in primary breast cancer. Japan J. Cancer Res. 1994; 85: 1045-1049.
26. Linderholm B, Tavelin B, Grankvist K, Henriksson R. Prognostic value of vascular endothelial growth factor protein in node-negative breast cancer. Eur. J. Cancer 1998; 34: S22.
27. Kufe D, Inghirami G, Abe M, Heyes D, Justi-Wheeler H, Schlom J. Differential reactivity of a novel monoclonal antibody (DF 3) with human malignant versus benign breast tumors. Hybridoma 1984; 3: 223-232.
28. Hilkens J, Kroenzen V, Bonfrer JMG, Brunning PF, Hilgers J, van Eijkeren W. A sandwich-radioimmunoassay for a new antigen (MAM 6) present in the sera of patients with metastased carcinomas. In Protides in the biological fluids, Peeters H (ed.). Pergamon: Oxford, 1984; 651-653.
29. Gold P, Freedman SO. Specific carcinoembryonic antigen gene family: structure expression and evolution. Tumor Biol. 1988; 9: 467-481.
30. Björklund B, Björklund V. Antigenicity of pooled human malignant and normal tissues by cyto-immunological technique: presence of an insoluble heat-labile tumor antigen. Int. Arch. Allergy 1957; 10: 153-184.